# A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

> **NCT01936688** · PHASE3 · WITHDRAWN · sponsor: **Sun Pharmaceutical Industries Limited**

## Conditions studied

- Plaque-type Psoriasis

## Interventions

- **DRUG:** MK-3222 200 mg
- **DRUG:** MK-3222 100 mg
- **DRUG:** Placebo to MK-3222
- **DRUG:** Placebo to Etanercept
- **DRUG:** Etanercept 50 mg

## Key facts

- **NCT ID:** NCT01936688
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-09
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01936688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01936688, "A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01936688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*